Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07356245 · ClinicalTrials.gov registry record · Phase 2

Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma

A Phase 2 study of Graft-Versus-Host Disease and Peripheral T-Cell Lymphoma, sponsored by Jonathan Brammer.

Recruiting
Registry status
Phase 2
Development phase
44
Enrollment target
1
Study location

NCT07356245 is a Phase 2 study of Graft-Versus-Host Disease and Peripheral T-Cell Lymphoma that is actively recruiting participants, run by Jonathan Brammer. The registered enrollment target is 44 participants, below the 82-participant average among 38 other Graft-Versus-Host Disease trials with a reported enrollment target (46% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07356245, a Phase 2 study of Graft-Versus-Host Disease and Peripheral T-Cell Lymphoma, is actively recruiting participants, sponsored by Jonathan Brammer.

RECRUITING
Registry status
Phase 2
Development phase
44 participants
Enrollment target
1
Study location

Study Summary

This phase II trial tests how well ruxolitinib as a maintenance medication works to prevent relapse and graft-versus-host disease (GVHD) for patients who have undergone stem cell transplantation for T-cell lymphoma. GVHD is a common problem that may occur after a blood stem cell transplant. The "graft" is the donor blood cells that patients get during the transplant. The "host" is the person receiving the cells. GVHD is when the donor graft attacks and damages some of the transplant recipient's tissues. Ruxolitinib is a type of drug called a Janus kinase (JAK) inhibitor which works by decreasing the immune response of cells in the body. It is also a cancer growth blocker that blocks the growth factors that trigger the cancer cells to divide and grow. Ruxolitinib works by blocking a gene, called JAK2, that is important in the production of cancer cells.

Conditions Studied

Graft-Versus-Host Disease Peripheral T-Cell Lymphoma Cutaneous T Cell Lymphoma T-Cell Lymphoma Lymphoma, T-Cell T-cell-prolymphocytic Leukemia Adult T-cell Leukemia/Lymphoma Primary Cutaneous T-Cell Non-Hodgkin Lymphoma

Interventions

  • PROCEDURE Biospecimen Collection
  • PROCEDURE Bone Marrow Biopsy
  • PROCEDURE Biopsy Procedure
  • DRUG Ruxolitinib
  • PROCEDURE Positron emission tomography-computed tomography

Study Locations (1)

Ohio

  • Ohio State University Comprehensive Cancer Center - Columbus

Trial Details

FieldValue
Enrollment Target 44 participants
Start Date 2026-02-01
Est. Completion 2027-01-31
Phase Phase 2

Sponsor

Jonathan Brammer

3 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07356245

The ClinicalTrials.gov registry entry for NCT07356245 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 82-participant average among 38 other Graft-Versus-Host Disease trials with a reported enrollment target (46% lower). The listed sponsor is Jonathan Brammer, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 8 conditions, with Graft-Versus-Host Disease appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.

NCT07356245 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT07356245 about?

NCT07356245 is a clinical study titled "Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma". This phase II trial tests how well ruxolitinib as a maintenance medication works to prevent relapse and graft-versus-host disease (GVHD) for patients who have undergone stem cell transplantation for T-cell lymphoma. GVHD is a common problem that may occur after a blood stem cell transplant. The "gra...

What is the current status of trial NCT07356245?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2026-02-01. Estimated completion is 2027-01-31.

What conditions does trial NCT07356245 study?

This clinical trial studies the following conditions: Graft-Versus-Host Disease, Peripheral T-Cell Lymphoma, Cutaneous T Cell Lymphoma, T-Cell Lymphoma, Lymphoma, T-Cell.

What interventions are being tested in trial NCT07356245?

The interventions under investigation include: Biospecimen Collection (PROCEDURE), Bone Marrow Biopsy (PROCEDURE), Biopsy Procedure (PROCEDURE), Ruxolitinib (DRUG), Positron emission tomography-computed tomography (PROCEDURE).

Who is sponsoring clinical trial NCT07356245?

This trial is sponsored by Jonathan Brammer, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07356245 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Graft-Versus-Host Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Graft-Versus-Host Disease

All registered trials for this condition

Peripheral T-Cell Lymphoma

All registered trials for this condition

Ohio

All trials with a study site in Ohio

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.